Drug Database · Clinicians

Roxithromycin

Brands (4) Pulvid, Roxi-M, Roxisaph…Show all

Antibacterial (macrolide) PH FDA category

Rx · Prescription drug4 PH products Kidney dosing reviewed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals

Contraindications

  • Macrolide hypersensitivity
  • Severely impaired hepatic function
  • Ergot alkaloids
renalcarematters.com, reviewed

Dosing: Adult

  • Respiratory, ENT, skin and genital infections (adults): 300 mg once daily or 150 mg twice daily for 5 to 10 days
  • Severe hepatic insufficiency or cirrhosis: 150 mg once daily
renalcarematters.com, reviewed

Dosing: Altered kidney function

Roxithromycin is a macrolide eliminated mainly in feces (about 7% in urine). Its half-life lengthens from about 12 to 18 hours in kidney insufficiency, but the New Zealand data sheet does not require a dose reduction for the usual short course. Dose is halved in severe liver disease. It has no US FDA label.

Kidney function measure: The data sheet does not grade kidney impairment; bands shown on creatinine clearance (CrCl).

Show full dosing details
CrCl ≥60 mL/min
Usual: 300 mg/day (300 mg once daily or 150 mg twice daily) for 5 to 10 days; at least 10 days for streptococcal throat infection (data sheet).
CrCl 30–59 mL/min
No dose reduction needed for the usual short course; half-life about 18 hours in kidney insufficiency vs 12 hours in young adults (data sheet). About 7% of a dose is excreted in urine.
CrCl 15–29 mL/min
No dose reduction needed for the usual short course; half-life about 18 hours in kidney insufficiency vs 12 hours in young adults (data sheet). About 7% of a dose is excreted in urine.
CrCl <15 mL/min (not on dialysis)
No dose reduction needed for the usual short course; half-life about 18 hours in kidney insufficiency vs 12 hours in young adults (data sheet). About 7% of a dose is excreted in urine.
Hemodialysis (intermittent)
Dialysis not mentioned in the data sheet. Little renal elimination; no change expected for a short course.
Peritoneal dialysis
No change for a short course; not removed by CAPD (half-life about 21 hours; Lam 1995).
CRRT
Not mentioned.
  • Dialyzable? Not stated (92% to 96% protein-bound).
  • Monitoring QT risk factors (electrolyte disturbance common in kidney failure, bradycardia, QT drugs); INR with warfarin; digoxin levels and ECG (data sheet). Macrolide class warning: rare short-term risk of arrhythmia, myocardial infarction and cardiovascular death (data sheet 2025).
Children (kidney dosing)
Show full dosing details
eGFR ≥60
Usual weight-based dose (data sheet).
eGFR 30–59
No pediatric kidney data; adult data suggest no change for short courses.
eGFR 15–29
No pediatric kidney data; adult data suggest no change for short courses.
eGFR <15 (not on dialysis)
No pediatric kidney data; adult data suggest no change for short courses.
Hemodialysis (intermittent)
No pediatric data.
Peritoneal dialysis
No pediatric data.
CRRT
No pediatric data.

Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.

renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.

Source: Medsafe (New Zealand) product information (November 3, 2025). This generic has no US FDA label.

Dosing: Pediatric

Approved ages
Children (150 mg tablet only) (data sheet).
Usual dose
Children 40 kg and over: 150 mg twice daily (tablet data sheet). The data sheet gives no mg/kg dose for smaller children.

Kidney dosing in children: see Dosing: Altered kidney function.

renalcarematters.com, reviewed

Dosage forms

Philippines

  • Film-coated tablet: 150 mg

Registered products in the Philippines

4 products registered with the Food and Drug Administration (FDA) Philippines list Roxithromycin as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products4
Philippine FDA-registered products for Roxithromycin
Package insert
PulvidRoxithromycin
150 mg Film-Coated TabletStrip Foil x 10's (Box of 100's)
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Eadriex Pharmaceuticals, Phils., Inc.
DR-XY33267
May 4, 2027
Roxi-MRoxithromycin
150 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's)
Rx
ZIM LABORATORIES LTD.India
DIAFARM INC.Trader: RAINBOW LIFE SCIENCES PVT. LTD.
DRP-4171
Jan 3, 2028
RoxisaphRoxithromycin
150 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 10's)
Rx
SAPPHIRE LIFESCIENCES PVT. LTDIndia
NELPA LIFESCIENCES, INC.
DRP-8381
Sep 18, 2028
RoxithinRoxithromycin
150 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's)
Rx
Brawn Laboratories LimitedIndia
Ambica International Corporation
DRP-4488
Jun 18, 2028

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Drug interactions

Drug or classSeverityEffectWhat to do
Ergotamine, dihydroergotamineAvoidErgotism.Contraindicated.
Terfenadine, astemizole, cisapride, pimozideAvoidQT prolongation.Not recommended.
Class IA and III antiarrhythmics, disopyramideAdjust or monitorQT prolongation; higher disopyramide levels.Use with caution; ECG.
WarfarinAdjust or monitorINR rise; severe bleeding reported.Monitor INR.
DigoxinAdjust or monitorHigher digoxin levels.Monitor ECG and levels.
Midazolam, theophylline, cyclosporine, rifabutin, bromocriptineMinorModest rises (weak CYP3A4 inhibition).Monitor.

Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.

renalcarematters.com, reviewed

Adverse reactions

Common

  • Nausea, vomiting, diarrhea, abdominal pain

Serious

  • QT prolongation, torsades de pointes
  • Stevens-Johnson syndrome, toxic epidermal necrolysis
  • Hepatitis (raised transaminases)
renalcarematters.com, reviewed

Monitoring parameters

  • QT risk factors (electrolyte disturbance common in kidney failure, bradycardia, QT drugs); INR with warfarin; digoxin levels and ECG (data sheet). Macrolide class warning: rare short-term risk of arrhythmia, myocardial infarction and cardiovascular death (data sheet 2025). Kidney
  • QT risk factors
  • INR with warfarin
renalcarematters.com, reviewed

Pharmacokinetics

Key PK parameters

BioavailabilityAbout 50%
Half-lifeAbout 12 hours (young adults); 20 hours in children; 27 hours in older adults
Half-life in kidney failure (ESKD) kidneyAbout 18 hours in kidney insufficiency
Protein binding92% to 96% (alpha-1-acid glycoprotein)
Renal excretion kidneyAbout 7% in urine; 53% in feces; 13% via lungs
Dialyzability kidneyNot stated
renalcarematters.com, reviewed

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. Medsafe (New Zealand Medicines and Medical Devices Safety Authority). Arrow-Roxithromycin tablets data sheet [Medsafe (New Zealand) product information, November 3, 2025; no US FDA label]. https://www.medsafe.govt.nz/Profs/datasheet/a/ArrowRoxithromycintab.pdf
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. Teva Pharma (New Zealand) Limited. (2025). Arrow-Roxithromycin 150 mg and 300 mg tablets [New Zealand data sheet; revised November 3, 2025]. Medsafe, New Zealand Medicines and Medical Devices Safety Authority. https://www.medsafe.govt.nz/Profs/datasheet/a/ArrowRoxithromycintab.pdf
  4. Lam, Y. W., Flaherty, J. F., Yumena, L., Schoenfeld, P. Y., & Gambertoglio, J. G. (1995). Roxithromycin disposition in patients on continuous ambulatory peritoneal dialysis. Journal of Antimicrobial Chemotherapy, 36(1), 157–163. https://doi.org/10.1093/jac/36.1.157

renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .